



Repatha

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155.** If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date:** _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____ **NPI#:** _____
Specialty: _____ **Physician Office Fax:** _____
Physician Office Telephone: _____
Request Initiated For: _____

1. What is the diagnosis?
 - Primary hyperlipidemia
 - Heterozygous familial hypercholesterolemia (HeFH)
 - Homozygous familial hypercholesterolemia (HoFH)
 - Other _____
2. What is the ICD-10 code? _____
3. What is the current LDL-C level? _____ mg/dL ***ACTION REQUIRED: Attach chart notes indicating the current treated LDL-C level. The LDL-C level must be dated within the six months preceding the authorization request.***
4. Does the patient have a history of clinical atherosclerotic cardiovascular disease (ASCVD)?
 Yes No
5. Is this request for continuation of therapy with a PCSK9 inhibitor? Yes No *If No, skip to #7*
6. Has the patient achieved or maintained an LDL-C reduction (e.g., LDL-C now at goal, robust reduction in LDL-C) as a result of PCSK9 inhibitor therapy? Yes No *No further questions.*
7. Is the patient receiving a high-intensity statin dose daily, such as rosuvastatin (Crestor) 20 mg daily or atorvastatin (Lipitor) 40 mg? Yes No *If No, skip to #10*
8. Has the patient received this dose for at least 3 months? Yes No *If No, skip to #10*
9. Has the patient received the high-intensity statin dose for at least 3 months in combination with ezetimibe?
If Yes, skip to #17 Yes No
10. Was the patient unable to tolerate a high-intensity statin due to adverse effects?
 Yes No *If No, skip to #14*
11. Is the patient receiving a moderate-intensity statin dose daily, such as atorvastatin (Lipitor) 20 mg or equivalent?
 Yes No *If No, skip to #14*
12. Has the patient received this dose for at least 3 months? Yes No *If No, skip to #14*

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Repatha Enhanced SGM - 7/2023.

CVS Caremark Prior Authorization • 1300 E. Campbell Road • Richardson, TX 75081

Phone: 1-866-814-5506 • Fax: 1-866-249-6155 • www.caremark.com

13. Has the patient received the moderate-intensity statin dose for at least 3 months in combination with ezetimibe?
If Yes, skip to #17 Yes No
14. Did the patient score a 7 or higher on the Statin-Associated Muscle Symptom Clinical Index (SAMS-CI)? **ACTION REQUIRED: Attach chart notes confirming the SAMS-CI score.** If Yes, skip to #17 Yes No
15. Did the patient experience a statin-associated increase in creatine kinase (CK) level to greater than or equal to 10 times the upper limit of normal (ULN) during previous treatment with a statin? **ACTION REQUIRED: Attach chart notes confirming the CK levels.** If Yes, skip to #17 Yes No
16. Does the patient have any of the following contraindications to statins? **ACTION REQUIRED: Attach chart notes confirming the contraindication.**
- Active liver disease, including unexplained persistent elevations in hepatic transaminase levels (e.g., ALT greater than or equal to 3 times upper limit of normal)
 - Currently pregnant
 - May become pregnant
 - Breastfeeding
 - None of the above
17. If the patient has a history of clinical atherosclerotic cardiovascular disease (ASCVD), which of the manifestations of clinical atherosclerotic cardiovascular disease (ASCVD) has the patient experienced?
ACTION REQUIRED: Attach chart notes confirming clinical atherosclerotic cardiovascular disease.
If N/A, continue to #18. For all other answers, no further questions.
- Acute coronary syndromes
 - Stroke of presumed atherosclerotic origin
 - Myocardial infarction
 - Transient ischemic attack (TIA)
 - Stable or unstable angina
 - Coronary or other arterial revascularization procedure (e.g., percutaneous coronary intervention [PCI], coronary artery bypass graft [CABG] surgery)
 - Non-cardiac peripheral arterial disease of presumed atherosclerotic origin (e.g., carotid artery stenosis, lower extremity PAD)
 - Obstructive coronary artery disease (defined as fifty percent or greater stenosis on cardiac computed tomography angiogram or catheterization)
 - Coronary Artery Calcium (CAC) score of greater than or equal to 1000
 - Other _____
 - N/A, patient does not have a history of clinical atherosclerotic cardiovascular disease (ASCVD)
18. What is the patient's untreated (before any lipid-lowering therapy) LDL-C level? **ACTION REQUIRED: Attach chart notes indicating the untreated LDL-C level.**
- Greater than or equal to 190 mg/dL
 - Greater than or equal to 160 mg/dL but less than 190 mg/dL
 - Less than 160 mg/dL
19. Are there any secondary causes that could explain the elevated untreated LDL-C? Yes No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X _____

Prescriber or Authorized Signature

Date (mm/dd/yy)

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Repatha Enhanced SGM - 7/2023.

CVS Caremark Prior Authorization • 1300 E. Campbell Road • Richardson, TX 75081

Phone: 1-866-814-5506 • Fax: 1-866-249-6155 • www.caremark.com